0LOV.LSE Verastem, Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -285.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0LOV.LSE undervalued?
Graham numberThe Graham number of Verastem, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Verastem, Inc. fundamental analysis
No fundamental analysis for Verastem, Inc. yet.
Verastem, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Verastem, Inc.
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactini…
Full company profileVerastem, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Verastem, Inc. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | 26.7M | 17.5M | 18.5M | 606K | 2.60M | - | 10.0M | 30.9M | 117M |
| Gross Profit | -670K | -556K | 25.1M | 14.2M | 15.4M | 400K | 2.48M | -62.0K | 9.97M | 25.6M | 104M |
| Operating Income | -37.0M | -67.8M | -94.8M | -132M | -83.4M | -62.9M | -75.5M | -92.1M | -115M | -170M | -155M |
| EBITDA | -36.3M | -67.2M | -93.4M | -130M | -50.4M | -61.2M | -72.8M | -92.0M | -126M | -169M | -154M |
| Net Income | -36.4M | -67.8M | -72.4M | -149M | -67.7M | -71.2M | -73.8M | -87.4M | -131M | -209M | -143M |
| EPS | -12 | -21 | -13 | -24 | -5.30 | -4.90 | -4.57 | -3.96 | -3.66 | -3.02 | -1.42 |
| Balance Sheet | |||||||||||
| Total Assets | 83.6M | 89.8M | 277M | 145M | 154M | 109M | 95.1M | 150M | 102M | 246M | 207M |
| Total Liabilities | 11.3M | 32.1M | 153M | 138M | 39.1M | 21.1M | 47.7M | 71.2M | 130M | 189M | 157M |
| Shareholders' Equity | 72.3M | 57.7M | 124M | 7.17M | 115M | 87.6M | 47.4M | 78.5M | -28.9M | 57.2M | 50.0M |
| Cash & Short-term Investments | 80.9M | 86.8M | 250M | 75.5M | 141M | 100M | 87.9M | 137M | 88.8M | 205M | 136M |
| Total Debt | - | 14.8M | 120M | 108M | 22.5M | 3.18M | 27.1M | 45.7M | 42.3M | 87.2M | 84.3M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -29.5M | -57.3M | -74.5M | -139M | -35.3M | -53.5M | -63.7M | -86.5M | -105M | -138M | -192M |
| Capital Expenditure | 39.0K | 0.00 | 23.5M | 7.00K | 33.0K | 196K | 0.00 | 0.00 | 28.0K | 0.00 | 0.00 |
| Free Cash Flow | -29.5M | -57.3M | -98.0M | -139M | -35.3M | -53.7M | -63.7M | -86.5M | -105M | -138M | -192M |
| Ratios | |||||||||||
| ROE | -50.4% | -117.5% | -58.3% | -2,079.9% | -58.8% | -81.3% | -155.8% | -111.2% | - | -366.2% | -285.1% |
| ROA | -43.6% | -75.5% | -26.1% | -102.9% | -43.9% | -65.5% | -77.7% | -58.4% | -128.7% | -85.0% | -69.0% |
| Net Profit Margin | - | - | -271.1% | -854.8% | -365.8% | -11,749.2% | -2,843.3% | - | -1,306.4% | -677.6% | -121.3% |
| Debt to Equity | - | 0.26x | 0.97x | 14.99x | 0.20x | 0.04x | 0.57x | 0.58x | - | 1.52x | 1.69x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Verastem, Inc. dividends
Verastem, Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 0.083333:1 on Jun 1, 2023.
Who owns Verastem, Inc.
- Insiders 0.81%
- Institutions 82.53%
- Public & others 16.66%
- Free float 79.9M
Verastem, Inc. company profile
- Company name
- Verastem, Inc.
- Ticker
- 0LOV.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 102
- Fiscal year end
- December
- Address
- 117 Kendrick Street, Needham, MA, United States, 02494
- Phone
- 781 292 4200
- Website
- verastem.com
About Verastem, Inc.
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Verastem, Inc. management
10- Mr. Daniel W. PatersonPresident, CEO & Director · born 1961
- Mr. Daniel CalkinsChief Financial Officer · born 1988
- Dr. Michael Glen Kauffman M.D., Ph.D.President of Development & Director · born 1963
- Dr. Robert A. Weinberg Ph.D.Co-Founder & Chair of Scientific Advisory Board
- Dr. Michelle Detwiler M.D., Ph.D.Co-Founder · born 1976
- Ms. Lori HorvatExecutive Vice President of Portfolio Strategy & Operations
- Dr. Jonathan Pachter Ph.D.Chief Scientific Officer · born 1958
- Ms. Julissa VianaSenior Vice President of Corporate Communications, Investor Relations & Patient Advocacy
- Mr. Mark J. WandaSenior VP of Legal & Chief Compliance Officer
- Ms. Cathy CarewChief Organizational Effectiveness Officer